Constructor vs Kenvue
Side-by-side comparison of AI visibility scores, market position, and capabilities
San Francisco AI product discovery platform founded 2015; raised $55M+; optimizes ecommerce search and browse directly for revenue and conversion KPIs rather than abstract relevance scores.
About
Constructor was founded in 2015 in San Francisco and raised over $55M to build an AI-powered product discovery platform targeting large e-commerce companies and retailers with revenue-optimization as the primary value proposition. Constructor differentiates from other e-commerce search vendors by explicitly framing its search algorithm not around relevance as an end goal but around business outcome optimization — its models are trained to maximize revenue, conversions, or other commerce KPIs rather than abstract relevance scores.\n\nConstructor's platform covers product search, browse, recommendations, and collections, with a unified AI layer that shares signals across all product discovery touchpoints rather than treating search and browse as separate problems. The platform is designed for high-traffic, catalog-rich e-commerce operations where even small improvements in discovery quality translate to significant incremental revenue. Constructor offers a quorum-based infrastructure designed to maintain performance at enterprise scale.\n\nConstructor targets large e-commerce companies and enterprise retailers, positioning itself above mid-market search vendors in terms of scale requirements and price point. The company counts major retailers and marketplace operators among its customers and competes against Coveo, Bloomreach Discovery, and in-house search solutions at large e-commerce companies. Its revenue-optimization framing and enterprise scalability are the primary differentiators versus more mid-market-focused competitors like Searchspring and Klevu.
Skillman NJ consumer health (NYSE: KVUE) ~$15.5B FY2024 revenue; J&J spinoff May 2023, Tylenol/Band-Aid/Neutrogena/Listerine/Aveeno portfolio, talc litigation exposure competing with Haleon and P&G.
About
Kenvue Inc. is a Skillman, New Jersey-based consumer health company — publicly traded on the New York Stock Exchange (NYSE: KVUE) as an S&P 500 Consumer Staples component — marketing and selling over-the-counter medicines, skin health and beauty products, and essential health products through iconic consumer brands including Tylenol (pain and fever relief), Band-Aid (wound care), Neutrogena (skin care), Johnson's (baby care), Listerine (oral care), Aveeno (skincare), Motrin/Advil (ibuprofen pain relief), Zyrtec (allergy), Nicorette (smoking cessation), Neosporin (antibiotic ointment), and Benadryl through approximately 22,000 employees in 165 countries. Kenvue was separated from Johnson & Johnson through an IPO in May 2023 (the largest US IPO of 2023) and a tax-free distribution of J&J's remaining 89.6% stake to J&J shareholders in August 2023 — creating the world's largest pure-play consumer health company by market capitalization, with J&J retaining no ownership. In fiscal year 2024, Kenvue reported revenues of approximately $15.5 billion, with organic growth facing headwinds from lower cold/cough/flu season severity (Tylenol, Zyrtec, Benadryl volume sensitive to respiratory illness intensity), competitive pressure in skin health (Neutrogena competing with Korean beauty brands, Cerave, and pharmacy private label), and macroeconomic consumer trading down to lower-price alternatives in some markets. CEO Thibaut Mongon leads Kenvue's strategy of investing in the brand superiority of its household name portfolio while improving operational efficiency in the post-spinoff period (implementing Kenvue's own supply chain infrastructure, IT systems, and organizational structure previously shared with J&J).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.